Riik: Malaisia
keel: inglise
Allikas: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
Sodium Alginate; SSodium Bicarbonate__; Calcium Carbonate
HOVID BERHAD
Sodium Alginate; SSodium Bicarbonate__; Calcium Carbonate
2x6'stablet Tablets; 1 x 6's tablet Tablets; 10 x 6's tablet Tablets; 2x6s Tablets
HOVID BERHAD
_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP) _ GASCOVID FORTE TABLET 500MG SODIUM ALGINATE, 267MG SODIUM BICARBONATE, 160MG CALCIUM CARBONATE Page 1 of 2 WHAT IS IN THIS LEAFLET? 1. What Gascovid Forte Tablet is used for 2. How Gascovid Forte Tablet works 3. Before you use Gascovid Forte Tablet 4. How to use Gascovid Forte Tablet 5. While you are using Gascovid Forte Tablet 6. Side effects 7. Storage and Disposal of Gascovid Forte Tablet 8. Product description 9. Manufacturer and Product Registration Holder 10. Date of revision WHAT GASCOVID FORTE TABLET IS USED FOR Gascovid Forte Tablet is used for relief from the pain and discomfort of heartburn and acid indigestion. HOW GASCOVID FORTE TABLET WORKS Gascovid Forte Tablet belongs to a group of medicines called ‘reflux suppressants’, which form a protective layer on the top of the stomach contents to prevent stomach acid from escaping from the stomach where it works into the food pipe causing pain and discomfort. BEFORE YOU USE GASCOVID FORTE TABLET _- When you must not use it _ _ _ Do not take this medicine if: you know you are allergic to any of the ingredients as very rarely difficulty in breathing and skin rashes have occurred. Some of the symptoms of an allergic reaction may include: urticaria bronchospasm anaphylactic or anaphylactoid reactions Do not take this medicine after the expiry date printed on the pack or if the packaging is damaged. If you are not sure whether you should start taking this medicine, talk to your pharmacist or doctor. _Pregnancy and lactation _ _ _ Do not take Gascovid Forte Tablet if you are pregnant, trying to get pregnant or think you may be pregnant. Do not take Gascovid Forte Tablet if you are breast-feeding. Ask your doctor or pharmacist for advice before taking any medicine. _ _ _- Before you start use it _ This product contains sodium and calcium carbonate. Tell your doctor/pharmacist if: if you have been advised to follow a diet restricted in either of these if you suffer or have suffered from Lugege kogu dokumenti
xxx VIGASxx-x DESCRIPTION Round, 16mm, beige, mottled uncoated tablet, bevel-edged and flat faces. COMPOSITION Each tablet contains Sodium alginate 500mg, Sodium bicarbonate 267mg and Calcium carbonate 160mg. ACTIONS AND PHARMACOLOGY Pharmacotherapeutic classification: A02BX 13. Other drugs for peptic ulcer and gastro-oesophageal reflux disease. On ingestion Gascovid Forte Tablet react rapidly with gastric acid to form a raft of alginic acid gel having a near neutral pH and which floats on the stomach contents, quickly and effectively impeding gastro-oesophageal reflux, for up to 4 hours. In severe cases the raft itself may be refluxed into the oesophagus, in preference to the stomach contents, and exert a demulcent effect. PHARMACOKINETICS The mode of action of Gascovid Forte Tablet is physic al and does not depend on absorption into the systemic circulation. INDICATIONS Relief from the pain and discomfort of heartburn and acid indigestion. CONTRAINDICATIONS This medicinal product is contraindicated in patients with known or suspected hypersensitivity to the active substances or to any of the excipients. PREGNANCY AND LACTATION Open controlled studies in 281 pregnant women did not demonstrate any significant adverse effects of Gascovid Forte Tablet on the course of pregnancy or on the health of the foetus or new-born child. Based on this Gascovid Forte Tablet may be used during pregnancy and lactation. PRECAUTIONS This product contains sodium. This should be taken into account when a highly restricted salt diet is recommended, e.g. in some cases of congestive cardiac failure and renal impairment. This product contains calcium carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi. There is a possibility of reduced efficacy in patients with very low levels of gastric acid. If symptoms do not improve after seven days, the clinical situation should be reviewed. Treatment of children younger than 12 years of age is not generally rec Lugege kogu dokumenti